Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Database
Language
Publication year range
1.
Tuberculosis (Edinb) ; 116: 44-55, 2019 05.
Article in English | MEDLINE | ID: mdl-31153518

ABSTRACT

Low molecular weight (LMW) thiols are molecules with a functional sulfhydryl group that enable them to detoxify reactive oxygen species, reactive nitrogen species and other free radicals. Their roles range from their ability to modulate the immune system to their ability to prevent damage of biological molecules such as DNA and proteins by protecting against oxidative, nitrosative and acidic stress. LMW thiols are synthesized and found in both eukaryotes and prokaryotes. Due to their beneficial role to both eukaryotes and prokaryotes, their specific functions need to be elucidated, most especially in pathogenic prokaryotes such as Mycobacterium tuberculosis (M.tb), in order to provide a rationale for targeting their biosynthesis for drug development. Ergothioneine (ERG), mycothiol (MSH) and gamma-glutamylcysteine (GGC) are LMW thiols that have been shown to interplay to protect M.tb against cellular stress. Though ERG, MSH and GGC seem to have overlapping functions, studies are gradually revealing their unique physiological roles. Understanding their unique physiological role during the course of tuberculosis (TB) infection, would pave the way for the development of drugs that target their biosynthetic pathway. This review identifies the knowledge gap in the unique physiological roles of LMW thiols and proposes their mechanistic roles based on previous studies. In addition, it gives an update on identified inhibitors of their biosynthetic enzymes.


Subject(s)
Mycobacterium tuberculosis/metabolism , Sulfhydryl Compounds/metabolism , Tuberculosis/microbiology , Animals , Antitubercular Agents/therapeutic use , Cysteine/metabolism , Dipeptides/metabolism , Enzyme Inhibitors/therapeutic use , Enzymes/metabolism , Ergothioneine/metabolism , Glycopeptides/metabolism , Humans , Inositol/metabolism , Molecular Targeted Therapy , Molecular Weight , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/pathogenicity , Tuberculosis/drug therapy
2.
Sci Data ; 5: 180184, 2018 09 25.
Article in English | MEDLINE | ID: mdl-30251996

ABSTRACT

Mycothiol (MSH) and ergothioneine (ERG) are thiols able to compensate for each other to protect mycobacteria against oxidative stress. Gamma-glutamylcysteine (GGC), another thiol and an intermediate in ERG biosynthesis has detoxification abilities. Five enzymes are involved in ERG biosynthesis, namely EgtA, EgtB, EgtC, EgtD and EgtE. The role of these enzymes in the production of ERG had been unclear. On the other hand, the enzyme MshA is known to be essential for MSH biosynthesis. In this manuscript, we describe the raw data of the generation and characterization of Mycobacterium tuberculosis (M.tb) mutants harbouring a deletion of the gene coding for each of these enzymes, and the raw data of the phenotypic characterization of the obtained thiol-deficient M.tb mutants. High throughput screening (HTS) of off-patent drugs and natural compounds revealed few compounds that displayed a higher activity against the thiol-deficient mutants relative to the wild-type strain. The mode of action of these drugs was further investigated. Raw data displaying these results are described here.


Subject(s)
Cysteine/deficiency , Cysteine/genetics , Dipeptides/deficiency , Dipeptides/genetics , Ergothioneine/deficiency , Ergothioneine/genetics , Glycopeptides/deficiency , Glycopeptides/genetics , Inositol/deficiency , Inositol/genetics , Mycobacterium tuberculosis , Bacterial Proteins/chemistry , Bacterial Proteins/genetics , Mutation , Mycobacterium tuberculosis/chemistry , Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/isolation & purification , Oxidative Stress/genetics , Sulfhydryl Compounds
3.
J Biomed Sci ; 25(1): 55, 2018 Jul 12.
Article in English | MEDLINE | ID: mdl-30001196

ABSTRACT

BACKGROUND: Three low molecular weight thiols are synthesized by Mycobacterium tuberculosis (M.tb), namely ergothioneine (ERG), mycothiol (MSH) and gamma-glutamylcysteine (GGC). They are able to counteract reactive oxygen species (ROS) and/or reactive nitrogen species (RNS). In addition, the production of ERG is elevated in the MSH-deficient M.tb mutant, while the production of MSH is elevated in the ERG-deficient mutants. Furthermore, the production of GGC is elevated in the MSH-deficient mutant and the ERG-deficient mutants. The propensity of one thiol to be elevated in the absence of the other prompted further investigations into their interplay in M.tb. METHODS: To achieve that, we generated two M.tb mutants that are unable to produce ERG nor MSH but are able to produce a moderate (ΔegtD-mshA) or significantly high (ΔegtB-mshA) amount of GGC relative to the wild-type strain. In addition, we generated an M.tb mutant that is unable to produce GGC nor MSH but is able to produce a significantly low level of ERG (ΔegtA-mshA) relative to the wild-type strain. The susceptibilities of these mutants to various in vitro and ex vivo stress conditions were investigated and compared. RESULTS: The ΔegtA-mshA mutant was the most susceptible to cellular stress relative to its parent single mutant strains (ΔegtA and ∆mshA) and the other double mutants. In addition, it displayed a growth-defect in vitro, in mouse and human macrophages suggesting; that the complete inhibition of ERG, MSH and GGC biosynthesis is deleterious for the growth of M.tb. CONCLUSIONS: This study indicates that ERG, MSH and GGC are able to compensate for each other to maximize the protection and ensure the fitness of M.tb. This study therefore suggests that the most effective strategy to target thiol biosynthesis for anti-tuberculosis drug development would be the simultaneous inhibition of the biosynthesis of ERG, MSH and GGC.


Subject(s)
Cysteine/biosynthesis , Dipeptides/biosynthesis , Ergothioneine/biosynthesis , Glycopeptides/biosynthesis , Inositol/biosynthesis , Tuberculosis/microbiology , Animals , Cysteine/antagonists & inhibitors , Cysteine/genetics , Dipeptides/antagonists & inhibitors , Dipeptides/genetics , Ergothioneine/antagonists & inhibitors , Ergothioneine/genetics , Glycopeptides/antagonists & inhibitors , Glycopeptides/genetics , Humans , Inositol/antagonists & inhibitors , Inositol/genetics , Mice , Molecular Weight , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/pathogenicity , Oxidative Stress , Reactive Nitrogen Species/metabolism , Reactive Oxygen Species/metabolism , Sulfhydryl Compounds/chemistry , Sulfhydryl Compounds/metabolism , Tuberculosis/drug therapy , Tuberculosis/genetics , Tuberculosis/pathology
4.
Article in English | MEDLINE | ID: mdl-29437626

ABSTRACT

The high acquisition rate of drug resistance by Mycobacterium tuberculosis necessitates the ongoing search for new drugs to be incorporated in the tuberculosis (TB) regimen. Compounds used for the treatment of other diseases have the potential to be repurposed for the treatment of TB. In this study, a high-throughput screening of compounds against thiol-deficient Mycobacterium smegmatis strains and subsequent validation with thiol-deficient M. tuberculosis strains revealed that ΔegtA and ΔmshA mutants had increased susceptibility to azaguanine (Aza) and sulfaguanidine (Su); ΔegtB and ΔegtE mutants had increased susceptibility to bacitracin (Ba); and ΔegtA, ΔmshA, and ΔegtB mutants had increased susceptibility to fusaric acid (Fu). Further analyses revealed that some of these compounds were able to modulate the levels of thiols and oxidative stress in M. tuberculosis This study reports the activities of Aza, Su, Fu, and Ba against M. tuberculosis and provides a rationale for further investigations.


Subject(s)
Antitubercular Agents/pharmacology , Mycobacterium tuberculosis/drug effects , Azaguanine/pharmacology , Mutation/genetics , Mycobacterium tuberculosis/genetics , Oxidative Stress/drug effects , Oxidative Stress/genetics , Sulfaguanidine/pharmacology , Sulfhydryl Compounds/metabolism
5.
Biochem Biophys Res Commun ; 495(1): 174-178, 2018 01 01.
Article in English | MEDLINE | ID: mdl-29101028

ABSTRACT

Mycobacterium tuberculosis (M.tb.), the causative agent of tuberculosis (TB), cannot synthesize GSH, but synthesizes two major low molecular weight thiols namely mycothiol (MSH) and ergothioneine (ERG). Gamma-glutamylcysteine (GGC), an intermediate in GSH synthesis, has been implicated in the protection of lactic acid bacteria from oxidative stress in the absence of GSH. In mycobacteria, GGC is an intermediate in ERG biosynthesis, and its formation is catalysed by EgtA (GshA). GGC is subsequently used by EgtB in the formation of hercynine-sulphoxide-GGC. In this study, M.tb. mutants harbouring unmarked, in-frame deletions in each of the fives genes involved in ERG biosynthesis (egtA, egtB, egtC, egtD and egtE) or a marked deletion of the mshA gene (required for MSH biosynthesis) were generated. Liquid chromatography tandem mass spectrometry analyses (LC-MS) revealed that the production of GGC was elevated in the MSH-deficient and the ERG-deficient mutants. The ERG-deficient ΔegtB mutant which accumulated GGC was more resistant to oxidative and nitrosative stress than the ERG-deficient, GGC-deficient ΔegtA mutant. This implicates GGC in the detoxification of reactive oxygen and nitrogen species in M.tb.


Subject(s)
Dipeptides/metabolism , Ergothioneine/genetics , Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/metabolism , Nitrosative Stress , Oxidative Stress , Biosynthetic Pathways , Cysteine/genetics , Cysteine/metabolism , Dipeptides/genetics , Ergothioneine/metabolism , Gene Deletion , Glycopeptides/genetics , Glycopeptides/metabolism , Humans , Inositol/genetics , Inositol/metabolism , Tuberculosis/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL